Replimune Group (NASDAQ:REPL) Upgraded at Leerink Partners

Leerink Partners upgraded shares of Replimune Group (NASDAQ:REPL) from a market perform rating to an outperform rating in a research note published on Monday morning, Marketbeat reports. The brokerage currently has $13.00 price objective on the stock, up from their prior price objective of $3.00.

A number of other analysts also recently issued reports on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Replimune Group in a report on Tuesday, October 14th. JPMorgan Chase & Co. reissued an “underweight” rating on shares of Replimune Group in a report on Friday, September 19th. Wedbush raised shares of Replimune Group from a “neutral” rating to an “outperform” rating and increased their price objective for the company from $4.00 to $18.00 in a report on Monday. BMO Capital Markets downgraded shares of Replimune Group from an “outperform” rating to an “underperform” rating and decreased their price objective for the company from $27.00 to $2.00 in a report on Wednesday, July 23rd. Finally, Jefferies Financial Group decreased their price objective on shares of Replimune Group from $31.00 to $6.00 and set a “buy” rating on the stock in a report on Tuesday, July 22nd. One research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, three have assigned a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $11.00.

Replimune Group Stock Up 2.5%

REPL stock opened at $8.30 on Monday. The firm’s fifty day simple moving average is $5.23 and its 200-day simple moving average is $7.29. The company has a market capitalization of $647.90 million, a P/E ratio of -2.56 and a beta of 0.42. The company has a debt-to-equity ratio of 0.21, a current ratio of 6.94 and a quick ratio of 6.94. Replimune Group has a 12 month low of $2.68 and a 12 month high of $17.00.

Replimune Group (NASDAQ:REPL) last announced its quarterly earnings results on Thursday, August 7th. The company reported ($0.95) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.83) by ($0.12). As a group, equities research analysts forecast that Replimune Group will post -2.97 earnings per share for the current year.

Insider Activity at Replimune Group

In other news, CFO Emily Luisa Hill sold 9,154 shares of the stock in a transaction dated Friday, August 15th. The shares were sold at an average price of $5.37, for a total value of $49,156.98. Following the completion of the sale, the chief financial officer directly owned 134,368 shares in the company, valued at $721,556.16. This represents a 6.38% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 5.20% of the stock is owned by company insiders.

Institutional Investors Weigh In On Replimune Group

Several hedge funds and other institutional investors have recently bought and sold shares of REPL. Moody Aldrich Partners LLC acquired a new stake in Replimune Group during the first quarter worth about $1,925,000. Bank of New York Mellon Corp increased its position in Replimune Group by 8.4% during the first quarter. Bank of New York Mellon Corp now owns 189,177 shares of the company’s stock worth $1,844,000 after purchasing an additional 14,659 shares during the last quarter. Arizona State Retirement System increased its position in Replimune Group by 19.7% during the first quarter. Arizona State Retirement System now owns 15,439 shares of the company’s stock worth $151,000 after purchasing an additional 2,545 shares during the last quarter. Victory Capital Management Inc. increased its position in Replimune Group by 67.4% during the first quarter. Victory Capital Management Inc. now owns 75,140 shares of the company’s stock worth $733,000 after purchasing an additional 30,260 shares during the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank increased its position in shares of Replimune Group by 106.2% during the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 11,410 shares of the company’s stock valued at $111,000 after acquiring an additional 5,876 shares during the last quarter. 92.53% of the stock is currently owned by institutional investors and hedge funds.

Replimune Group Company Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.